A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.
Latest Information Update: 08 Jun 2020
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms HiSCO-01
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 21 Apr 2019 Planned End Date changed from 31 May 2028 to 31 Mar 2019.
- 27 May 2018 Planned End Date changed from 1 Jun 2018 to 31 May 2028.